Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Jul;45 Suppl 1(Suppl 1):I40-4.
doi: 10.1136/gut.45.2008.i40.

Treatment after failure: the problem of "non-responders"

Affiliations
Review

Treatment after failure: the problem of "non-responders"

J Q Huang et al. Gut. 1999 Jul.

Abstract

Although the currently most effective treatment regimens cure about 90% of infections, 10% of patients remain Helicobacter pylori positive. Several factors contribute to treatment failure. These include patient compliance, bacterial resistance to antibiotics, and treatment related issues. Treatment failure leads to the development of bacterial resistance to metronidazole and clarithromycin. Retreatment can be undertaken after considering several different strategies: to repeat the same regimen with full doses of medications and a longer treatment duration, or to choose different regimens to avoid the antibiotic previously used, or to switch to proton pump inhibitor (PPI) based quadruple therapy or ranitidine bismuth citrate (RBC) based triple therapy. In principle, full doses and longer treatment durations are advisable. As retreatment is always difficult, choosing the best available first line treatment regimen is still the best "rescue" treatment.

PubMed Disclaimer

References

    1. Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):645-9 - PubMed
    1. Dig Dis Sci. 1997 Oct;42(10):2111-5 - PubMed
    1. Antimicrob Agents Chemother. 1994 Oct;38(10):2357-61 - PubMed
    1. Aliment Pharmacol Ther. 1995 Oct;9(5):513-20 - PubMed
    1. Am J Med. 1996 May 20;100(5A):42S-50S; discussion 50S-51S - PubMed